-- Reports Neurology Franchise Annual Net Sales of $110.3 million , at the High End of Guidance Range -- -- Files NDA for Long-Acting Cosyntropin and Receives FDA Notification of Acceptance -- -- Issues Full-Year 2019 Guidance for Earnings and Neurology Franchise Net Sales -- LAKE FOREST, Ill.

LAKE FOREST, Ill. , Feb. 21, 2019 (GLOBE NEWSWIRE) -- Assertio Therapeutics, Inc. (NASDAQ:ASRT) today announced that it will release fourth quarter and full year 2018 financial results on Wednesday, March 6, 2019 , after the close of markets. Following the announcement, the Company will host a

Company Anticipates Potential Market Launch by Early 2020 LAKE FOREST, Ill. , Feb. 19, 2019 (GLOBE NEWSWIRE) -- Assertio Therapeutics, Inc. (NASDAQ: ASRT) announced today that it has received notification of acceptance for filing from the U.S. Food and Drug Administration ( FDA ) for its 505(b)(2)

LAKE FOREST, Ill. , Feb. 19, 2019 (GLOBE NEWSWIRE) -- Assertio Therapeutics, Inc. (NASDAQ: ASRT) announced today that Heather L. Mason has been appointed to the Company’s Board of Directors. Ms. Mason is a former executive vice president of Abbott Laboratories .

Agreement Provides Greater Financial Flexibility as Company Continues to Reduce Debt LAKE FOREST, Ill. , Jan. 09, 2019 (GLOBE NEWSWIRE) -- Assertio Therapeutics, Inc. (NASDAQ: ASRT) today announced that it has amended its Senior Secured Credit Facility, replacing the previous fixed adjusted EBITDA

-- Submission Advances Company’s Strategy to Build A New Orphan/Specialty Business and Aligns with Company’s Mission of Putting Patients First -- LAKE FOREST, Ill. , Dec. 20, 2018 (GLOBE NEWSWIRE) -- Assertio Therapeutics, Inc. (NASDAQ: ASRT) today announced that it has submitted to the U.S.

-- Confirms Full-Year Net Sales Guidance Range for the Neurology Franchise -- -- Raises Full-Year Earnings Guidance and Confirms Adjusted EBITDA Guidance -- -- Amends and Strengthens Commercial Agreement with Collegium -- -- Confirms Regulatory Plan to File for FDA Approval of Cosyntropin Depot by

LAKE FOREST, Ill. , Oct. 29, 2018 (GLOBE NEWSWIRE) -- Assertio Therapeutics, Inc. (NASDAQ: ASRT) today announced that Phillip B. Donenberg, Senior Vice President and Chief Financial Officer, will retire effective November 30, 2018 . Replacing Mr. Donenberg will be Daniel A.

LAKE FOREST, Ill. , Oct. 17, 2018 (GLOBE NEWSWIRE) -- Assertio Therapeutics, Inc. (NASDAQ: ASRT), a leading specialty pharmaceutical company committed to advancing patient care, today announced that members of senior management will participate at the following investor conferences.

LAKE FOREST, Ill. , Oct. 08, 2018 (GLOBE NEWSWIRE) -- Assertio Therapeutics, Inc. (NASDAQ:ASRT) today announced that it will release third-quarter 2018 financial results on Thursday, November 8, 2018 , after the close of markets. Following the announcement, the Company will host a conference call